Psoriatic Arthritis
Conference Coverage
Secukinumab beat ustekinumab for psoriasis, with difference by week four
Key clinical point:Secukinumab achieved significantly better responses than ustekinumab in the treatment of moderate to severe psoriasis. Major...
Conference Coverage
Brodalumab achieved primary endpoints for moderate to severe psoriasis at 52 weeks
Key clinical point: At 52 weeks, brodalumab met its PASI 100 endpoint compared with ustekinumab in the pivotal phase III AMAGINE-2 trial. Major...
News
Halting biologics before surgery tied to flares in psoriasis, psoriatic arthritis
Key clinical point: Interrupting biologic therapy before surgery led to flares in psoriasis and psoriatic arthritis. Major finding: Discontinuing...
News
Interleukin-23 inhibition with tildrakizumab achieves significant psoriasis improvements
Video
VIDEO: Secukinumab ‘exciting’ new agent for psoriasis
News
Infliximab most common cause of drug-induced liver injury
Key clinical point: Infliximab was the most common anti–tumor necrosis factor-alpha agent linked to liver injury. Major finding: Rates of drug-...